Company Encyclopedia
View More
name
Stevanato Group SpA
STVN.US
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services.
755.08 B
STVN.USMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking9/62
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.19%B
    • Profit Margin12.01%B
    • Gross Margin29.29%C
  • Growth ScoreB
    • Revenue YoY9.36%B
    • Net Profit YoY25.32%B
    • Total Assets YoY14.53%A
    • Net Assets YoY14.16%A
  • Cash ScoreB
    • Cash Flow Margin832.45%B
    • OCF YoY9.36%B
  • Operating ScoreC
    • Turnover0.51C
  • Debt ScoreC
    • Gearing Ratio40.46%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Stevanato Group (NYSE:STVN) Sees Strong Trading Volume - Should You Buy?

    Stevanato Group (NYSE:STVN) saw a 17% increase in trading volume, with 376,600 shares traded. The stock last traded at €21.05. Analysts have mixed ratings: one Strong Buy, one Buy, and three Hold ratings, with a consensus rating of Moderate Buy. The company has a market cap of $6.34 billion and a P/E ratio of 36.79. Recent institutional investments include new stakes and increased holdings by several firms.

    Market Beat·
    US
    STVN
    +0.05%
    Market Beat·
    US
    STVN
    +0.05%

    Bank of America Securities Sticks to Their Buy Rating for Stevanato Group (STVN)

    Bank of America Securities analyst Michael Ryskin reiterated a Buy rating for Stevanato Group, setting a price target of $30.00. Ryskin, a 4-star analyst with a 4.2% average return, covers the Healthcare sector. The analyst consensus for Stevanato Group is a Moderate Buy with an average price target of $27.00.

    Tip Ranks·
    US
    STVN
    +0.05%
    Tip Ranks·
    US
    STVN
    +0.05%

    Morgan Stanley Sticks to Their Hold Rating for Stevanato Group (STVN)

    Morgan Stanley analyst Tejas Savant maintained a Hold rating for Stevanato Group with a $26.00 price target. Savant, a 3-star analyst, has a 1.6% average return and a 44.32% success rate. Stevanato Group also received a Hold rating from TR | OpenAI – 4o’s Jack Scalprey, while William Blair maintained a Buy rating.

    Tip Ranks·
    US
    STVN
    +0.05%
    Tip Ranks·
    US
    STVN
    +0.05%

    TimesSquare Capital Management LLC Sells 33,427 Shares of Stevanato Group S.p.A. $STVN

    TimesSquare Capital Management LLC reduced its stake in Stevanato Group S.p.A. by 1.0% in Q2, selling 33,427 shares. The firm now holds 3,325,539 shares, worth $81.24 million, making up 1.2% of its portfolio. Other investors like Envestnet, Raymond James, and LPL Financial also adjusted their holdings. Analysts have mixed ratings on STVN, with a consensus of 'Moderate Buy'.

    Market Beat·
    US
    STVN
    +0.05%
    Market Beat·
    US
    STVN
    +0.05%

    Stevanato Group’s Earnings Call Highlights Robust Growth

    Stevanato Group Spa (STVN) reported strong Q3 earnings, highlighting a 9% year-over-year revenue increase, driven by a 14% surge in its Biologics Drug Solutions segment. The high-value solutions segment grew by 47%, contributing significantly to total revenue. The company achieved margin expansion, with gross profit margins rising to 29.2%. However, the Engineering segment faced a 19% revenue decline. Despite challenges, Stevanato maintains its fiscal 2025 guidance, expecting revenue between $1.16 billion and $1.19 billion, supported by ongoing capacity expansions and a focus on high-value offerings.

    Tip Ranks·
    US
    STVN
    +0.05%
    Tip Ranks·
    US
    STVN
    +0.05%
    © 2025 Longbridge｜Disclaimer